(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
12 October 2023 (12.10.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/196342 A8

(51) International Patent Classification:
A61K 31/50 (2006.01) *A61K 31/33* (2006.01)
A61K 31/395 (2006.01) *A61K 31/16* (2006.01)
A61K 31/44 (2006.01)

(21) International Application Number:
PCT/US2023/017482

(22) International Filing Date:
04 April 2023 (04.04.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/327,334 04 April 2022 (04.04.2022) US

(71) Applicant: **ADARX PHARMACEUTICALS, INC.** [US/US]; 5871 Oberlin Drive, Suite 200, San Diego, CA 92121 (US).

(72) Inventors: **NUMA, Mehdi, Michel Djamel**; c/o ADARx Pharmaceuticals, Inc., 5871 Oberlin Drive, Suite 200, San Diego, CA 92121 (US). **LI, Zhen**; c/o ADARx Pharmaceuticals, Inc., 5871 Oberlin Drive, Suite 200, San Diego, CA 92121 (US). **ZHU, Rui**; c/o ADARx Pharmaceuticals, Inc., 5871 Oberlin Drive, Suite 200, San Diego, CA 92121 (US). **AZIMIOARA, Mihai**; c/o ADARx Pharmaceuticals, Inc., 5871 Oberlin Drive, Suite 200, San Diego, CA 92121 (US).

(74) Agent: **HSI, Jeffrey, D.** et al.; Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210-2206 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*

(48) Date of publication of this corrected version:
11 January 2024 (11.01.2024)

(15) Information about Correction:
see Notice of 11 January 2024 (11.01.2024)

(54) Title: $\alpha_4\beta_{1/7}$ INTEGRIN LIGAND CONJUGATED COMPOUNDS AND USES THEREOF




FIG. 7B

(57) Abstract: Provided herein are $\alpha_4\beta_{1/7}$ integrin receptor ligand-containing compounds, methods of delivering said compounds, and methods of treating diseases, disorders, and symptoms (*e.g.*, central nervous system diseases, disorders, and symptoms) in a subject using said compounds.

WO 2023/196342 A8